Back to results
US 6,730,477 B1Granted
Method of diagnosing, monitoring and staging breast cancer
AssigneediaDexus, Inc.
InventorsYongming Sun, Susana Salceda, Herve Recipon
Life of this patent
Estimating the term…
Abstract
The present invention provides a new method for detecting, diagnosing, monitoring, staging, and prognosticating breast cancer.
Claims13
A method for diagnosing the presence of breast cancer in a patient comprising:
- (a) measuring levels of a breast specific gene (BSG) in cells, tissues or bodily fluids in said patient;
- and
- (b) comparing measured levels of BSG with levels of BSG in cells, tissues or bodily fluids from a normal human control,
- wherein said BSG comprises SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8 or 9, a protein encoded thereby, or a polynucleotide which, due to degeneracy in genetic coding, comprises variations in nucleotide sequence as compared to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8 or 9, but which still encodes the same protein as SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8 or 9, and
- wherein a change in measured levels of BSG in the patient versus normal human control is associated with the presence of breast cancer.
4 more elements
A method of diagnosing metastatic breast cancer in a patient having breast cancer comprising:
- (a) identifying a patient having breast cancer that is not known to have metastasized;
- (b) measuring levels of a breast specific gene (BSG) in a sample of cells, tissues, or bodily fluid from said patient;
- and
- (c) comparing the measured BSG levels with levels of BSG in cells, tissue, or bodily fluid type of a normal human control,
- wherein said BSG comprises SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8 or 9, a protein encoded thereby, or a polynucleotide which, due to degeneracy in genetic coding, comprises variations in nucleotide sequence as compared to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8 or 9, but which still encodes the same protein as SEQ NO:
- 1, 2, 3, 4, 5, 6, 7, 8 or 9, and
- wherein a change in measured BSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.
5 more elements
A method of staging breast cancer in a patient comprising:
- (a) identifying a patient having breast cancer;
- (b) measuring levels of a breast specific gene (BSG) in a sample of cells, tissues, or bodily fluid from said patient for BSG;
- and
- (c) comparing measured BSG levels with levels of BSG in cells, tissues, or bodily fluid type of a normal human control sample,
- wherein said BSG comprises SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8 or 9, a protein encoded thereby, or a polynucleotide which, due to degeneracy in genetic coding, comprises variations in nucleotide sequence as compared to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8 or 9, but which still encodes the same protein as SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8 or 9, and
- wherein a change in measured BSG levels in said patient versus the normal human control is associated with a cancer which is progressing or regressing or in remission.
5 more elements
A method of monitoring breast cancer in a patient, having breast cancer for the onset of metastasis comprising:
- (a) identifying a patient having breast cancer that is not known to have metastasized;
- (b) periodically measuring breast specific gene (BSG) levels in a sample of cells, tissues, or bodily fluid from said patient;
- and
- (c) comparing the measured BSG levels with levels of BSG in cells, tissues, or bodily fluid type of a normal human control, wherein said BSG comprises SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8 or 9, a protein encoded thereby, or a polynucleotide which, due to degeneracy in genetic coding, comprises variations in nucleotide sequence as compared to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8 or 9, but which still encodes the same protein as SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8 or 9 and wherein a change in BSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.
3 more elements
A method of monitoring the change in stage of breast cancer in a patient having breast cancer comprising:
- (a) identifying a patient having breast cancer;
- (b) periodically measuring breast specific gene (BSG) levels in a sample of cells, tissues, or bodily fluid from said patient;
- and
- (c) comparing the measured BSG levels with levels of BSG in cells, tissues, or bodily fluid type of a normal human control,
- wherein said BSG comprises SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8 or 9, a protein encoded thereby, or a polynucleotide which, due to degeneracy in genetic coding, comprises variations in nucleotide sequence as compared to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8 or 9, but which still encodes the same protein as SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8 or 9, and
- wherein a change in measured BSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage, which is regressing in stage, or in remission.
5 more elements
Dependencies are inferred from the claim text.